Skip to search formSkip to main contentSkip to account menu

zoledronic acid

Known as: 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid, zoledronic acid [Chemical/Ingredient] 
A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid… 
National Institutes of Health

Related topics

Related topics

24 relations
100 ML zoledronic acid 0.05 MG/ML Injection100 ML zoledronic acid 0.05 MG/ML Injection [Reclast]5 ML zoledronic acid 0.8 MG/ML Injection5 ML zoledronic acid 0.8 MG/ML Injection [Zometa]

Broader (3)

Bone Density Conservation AgentsDiphosphonatesImidazoles

Narrower (6)

CGP 42446AReclastZOL 446Zometa

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis
IntroductionOsteoclasts play a key role in the pathogenesis of bone erosion and systemic bone mass loss during rheumatoid… 
Highly Cited
2008
Highly Cited
2008
Zoledronic acid infusion and orbital inflammatory disease.
A 57-year-old man presented with a 4-day history of increasing orbital pain and swelling in the right eye. A diagnosis of orbital… 
Highly Cited
2007
Highly Cited
2007
R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl‐2 and bad phosphorylation
Zoledronic acid (ZOL) has proved activity in bone metastases from prostate cancer through inhibition of mevalonate pathway and of… 
2006
2006
Simple analysis of four bisphosphonates simultaneously by reverse phase liquid chromatography using n-amylamine as volatile ion-pairing agent.
Highly Cited
2005
Highly Cited
2005
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid
Once bone metastasized and androgen independent, prostate cancer is often associated with skeletal morbidity and disability. New… 
Highly Cited
2005
Highly Cited
2005
Zoledronic acid down‐regulates adhesion molecules of bone marrow stromal cells in multiple myeloma
Myeloma plasma cells interact with the bone marrow microenvironment which, in turn, supports their growth and protects them from… 
Review
2004
Review
2004
Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care.
Highly Cited
2004
Highly Cited
2004
Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.
Highly Cited
2003
Highly Cited
2003
The Bisphosphonate Zoledronic Acid Induces Cytotoxicity in Human Myeloma Cell Lines with Enhancing Effects of Dexamethasone and Thalidomide
Bisphosphonates have recently been introduced in the therapeutic armamentarium for long-term treatment of patients with multiple… 
Review
2002
Review
2002
Preclinical pharmacology of zoledronic acid.
The evolution of bisphosphonates over the past 30 years has led to the development of nitrogen-containing bisphosphonates with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)